The 9 Wall Street analysts covering Aktis Oncology, Inc. hold a median 12-month price target of $35 — +57.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 19 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Aktis Oncology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (42): Analysts have, on balance, been raising their forecasts.
Quality (3): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on AKTS, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +57.7% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 9 Sept 2026 | Oppenheimer | Initiates | Outperform | $40 |
| 19 Aug 2026 | BMO Capital | Initiates | Outperform | $37 |
| 19 Aug 2026 | BMO Capital | Initiates | Outperform | — |
| 19 Aug 2026 | Wedbush | Initiates | Outperform | $35 |
| 19 Aug 2026 | Wedbush | Initiates | Outperform | — |
| 14 July 2026 | JP Morgan | Maintains | Overweight | $30 → $33 |
| 14 July 2026 | JP Morgan | Maintains | Overweight | — |
| 16 June 2026 | Raymond James | Initiates | Strong Buy | $40 |
| 16 June 2026 | Raymond James | Initiates | Strong Buy | — |
| 2 June 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 29 Apr 2026 | William Blair | Initiates | Outperform | — |
| 31 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 9 Mar 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 3 Feb 2026 | JP Morgan | Initiates | Overweight | — |
| 3 Feb 2026 | Leerink Partners | Initiates | Outperform | — |
| 4 Jan 2024 | Piper Sandler | Downgrade | Neutral | — |
| 7 Sept 2023 | B. Riley Securities | Downgrade | Neutral | — |
| 7 Sept 2023 | Oppenheimer | Maintains | Outperform | — |
| 9 May 2023 | Oppenheimer | Maintains | Outperform | — |
| 9 May 2023 | Roth MKM | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AKTS appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 96% of US stocks
Cheaper than 4% of US stocks
Cheaper than 38% of US stocks
Cheaper than 84% of US stocks
Higher than 93% of US stocks
Higher than 87% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
Higher than 92% of US stocks
Higher than 17% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Aktis Oncology, Inc. has a market value of $1.2B and an enterprise value of $765.4M.
Revenue in the twelve months to 30 June 2026: $10.1M. The latest quarter grew 111.4% year on year.
Net income over the same four quarters: −$73.1M, a −727.0% net margin.
Free cash flow in the twelve months to 30 June 2026: −$84.6M.
Trailing P/E: −18.1×; forward P/E: −10.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Aktis Oncology, Inc. employs 79 people — $127K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Aktis Oncology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Aktis Oncology, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation now available via Seeking Alpha.
Why it matters — Aktis Oncology watchers may gain insight into the company's current positioning from its remarks at a major financial healthcare conference.
Bank of America analysts said that a pullback in the AI trade has created opportunities for bargain-hunting investors, and they identified 16 knocked-down AI stocks as potential bargains. The excerpt does not name specific companies beyond the general AI-stock list.
Why it matters — The item does not mention Aktis Oncology or its business, so its direct relevance to AKTS watchers is limited to whether AKTS appears among the named stocks.
Aktis Oncology reported its financial results and business highlights for the second quarter ended June 30, 2026, in a press release on August 13, 2026.
Why it matters — The quarterly report provides a routine update on the company's financial position and operational progress for AKTS shareholders and potential investors.
The 9 Wall Street analysts covering Aktis Oncology, Inc. have a median 12-month price target of $35, with estimates ranging from $32 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 9 analysts covering Aktis Oncology, Inc., 9 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Aktis Oncology, Inc. 1 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.
As at 19 Sept 2026, Aktis Oncology, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (42 of 100).
No one can know that. What the data says: the median 12-month target from 9 analysts implies +57.7% from the last close, and Ticker Nerd's factor model ranks Aktis Oncology, Inc. 1 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Aktis Oncology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AKTS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $32 to $40 over the next 12 months.
Akoustis Technologies Inc. is a technology company specializing in the design, development, manufacture, and sale of radio frequency (RF) filter products for the wireless industry across the Americas, Asia, Europe, and other international markets.
The most recent item we track (Seeking Alpha, 16 Sept 2026): "Aktis Oncology, Inc. (AKTS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript". Aktis Oncology, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation now available via Seeking Alpha.
Akoustis Technologies Inc. is a technology company specializing in the design, development, manufacture, and sale of radio frequency (RF) filter products for the wireless industry across the Americas, Asia, Europe, and other international markets. It leverages proprietary bulk acoustic wave (BAW) technology, including its microelectromechanical system (MEMS)-based XBAW manufacturing process, to produce high-performance filters optimized for high power, high frequency, and wide bandwidth applications. The company operates through two primary segments: Fabrication Services, which offers engineering review and backend packaging services, and RF Filters, focused on amplifier and filter product sales. Its solutions serve critical applications in smartphones, tablets, cellular infrastructure equipment, Wi-Fi customer premise equipment, and military and defense systems. Akoustis Technologies Inc. also provides complementary products such as surface acoustic wave resonators, crystal resonators and oscillators, ceramic products, and back-end semiconductor supply chain services. Headquartered in Huntersville, North Carolina, the company plays a specialized role in advancing RF front-end modules for next-generation wireless connectivity.
CEO Dr. Matthew Roden Ph.D. · 79 employees · United States · https://www.aktisoncology.com
